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Abstract
Background: Mice irradiated and reconstituted with hematopoietic cells lacking manganese superoxide dismutase (SOD2)
show a persistent hemolytic anemia similar to human sideroblastic anemia (SA), including characteristic intra-mitochondrial
iron deposition. SA is primarily an acquired, clonal marrow disorder occurring in individuals over 60 years of age with
uncertain etiology.
Methodology/Principal Findings: To define early events in the pathogenesis of this murine model of SA, we compared
erythroid differentiation of Sod2
-/- and normal bone marrow cells using flow cytometry and gene expression profiling of
erythroblasts. The predominant transcriptional differences observed include widespread down-regulation of mitochondrial
metabolic pathways and mitochondrial biogenesis. Multiple nuclear encoded subunits of complexes I-IV of the electron
transport chain, ATP synthase (complex V), TCA cycle and mitochondrial ribosomal proteins were coordinately down-
regulated in Sod2
-/- erythroblasts. Despite iron accumulation within mitochondria, we found increased expression of
transferrin receptor, Tfrc, at both the transcript and protein level in SOD2 deficient cells, suggesting deregulation of iron
delivery. Interestingly, there was decreased expression of ABCb7, the gene responsible for X-linked hereditary SA with ataxia,
a component required for iron-sulfur cluster biogenesis.
Conclusions/Significance: These results indicate that in erythroblasts, mitochondrial oxidative stress reduces expression of
multiple nuclear genes encoding components of the respiratory chain, TCA cycle and mitochondrial protein synthesis. An
additional target of particular relevance for SA is iron:sulfur cluster biosynthesis. By decreasing transcription of components
of cluster synthesis machinery, both iron utilization and regulation of iron uptake are impacted, contributing to the
sideroblastic phenotype.
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Introduction
Reconstitution of mice with hematopoietic stem cells deficient in
manganese superoxide dismutase (SOD2) results in a hemolytic
anemia that recapitulates many features seen in patients with
sideroblastic anemia (SA) [1]. SA’s are a heterogeneous group of
inherited and acquired erythropoietic disorders with defining
features being the presence of bone marrow ringed sideroblasts
(RS), abnormal erythroblasts with pathologic mitochondrial iron
deposition, and impaired heme biosynthesis [2,3,4,5].
The molecular genetic basis for several of the inherited forms of
SA has been described. There are two X-linked sideroblastic
anemias (XLSAs), one caused by mutations of an erythroid-specific
form of the heme biosynthetic enzyme aminolevulinic acid-synthase
(ALAS2) [6], and one caused by mutation of a mitochondria-
localized transport protein, ATP-binding cassette, member b7
(ABCb7) [7]—that plays a role in maturation/transport of iron-
sulfur cluster containing proteins. Mutation of the pseudouridylate
synthase 1 gene (PUS1) was found to cause mitochondrial myopathy
and SA [8,9]. How this lesion specifically affects mitochondrial
function or iron metabolism is unclear—but it has been proposed
that pseudouridylation of small RNA’s distinct from tRNA may
affectmitochondrial function [10].Another type ofSApresenting in
infancy or childhood, Pearson marrow–pancreas syndrome, results
from a large deletion in mitochondrial DNA (mtDNA) [11] and
evolves features similar to the multi-system mitochondrial disorder
Kearn-Sayers syndrome. A single patient has been reported with a
splice site mutation in the glutaredoxin 5 gene (GLRX5) as a cause of
SA [12]. Most recently, mutations in a mitochondrial carrier family
gene (SLC25A38) have been identified in cases of hereditary SA
[13]. Analysis of SLC25A38 in a larger collection of hereditary SA
samples confirmed that this gene is involved in a significant fraction
(,15%) of hereditary SA cases, although a large number of cases
remain genetically undefined (.40%) [14].
The majority of cases of SA are acquired, occur in the context of
the bone marrow failure syndrome myelodysplasia (MDS) and
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where a defined genetic lesion has been identified, mitochondria
are also implicated in pathogenesis. Somatic point mutations of
mtDNA encoding subunit 1 of cytochrome c oxidase (COX1; i.e.,
complex IV of the respiratory chain) have been found in patients
with acquired idiopathic sideroblastic anemia (AISA) resulting in
measurable respiratory chain dysfunction [15]. There are reports
of mutations affecting other portions of the mtDNA including
cytochrome b or mitochondrial encoded tRNAs in isolated cases of
SA [16,17,18,19]. However, there remains considerable uncer-
tainty as to the role of acquired mtDNA mutations in SA and more
broadly in the pathogenesis of MDS [20].
Some cases of acquired, reversible SA have been associated with
specific drugs; the antibiotic chloramphenicol exerts its toxicity via
inhibition of mitochondrial protein synthesis, suppressing the bone
marrow, and can induce SA [21]; anti-tuberculosis therapy
interferes with pyridoxine metabolism, a cofactor for ALAS2,
and can result in SA [22,23]. Thus, both genetics and drug toxicity
data indicate that mitochondrial dysfunction plays a key role in the
etiology of SA. While specific mechanisms responsible for iron
overload in developing red cells remain poorly understood,
mitochondrial dysfunction (due to a diverse array of genetic
lesions or toxic exposures) appears to be both necessary and
sufficient to create a convergent phenotype of pathologic intra-
mitochondrial iron deposition that is characteristic of SA.
SOD2 is a mitochondrial antioxidant enzyme that detoxifies
superoxide anion radicals (O2
.-), a byproduct of mitochondrial
respiration. SOD2-deficiency induces severe mitochondrial dys-
function in neurons and muscle leading to embryonic or neonatal
lethality in homozygous mutant mice [24]. To analyze the impact
of SOD2-deficiency in hematopoietic tissues over long periods of
time, we have used fetal liver cells as a source of hematopoietic
stem cells (HSC) to reconstitute lethally irradiated mice [1].
Sod2
-/- HSC rescue irradiated wild-type recipients, however,
Sod2
-/- chimeric mice have a persistent hemolytic anemia. Sod2
-/-
red blood cells (RBC) show increased oxidative damage and have
a shortened lifespan [1]. Siderocytes (iron-loaded reticulocytes
found in marrow or peripheral blood of Sod2
-/- chimeric animals)
produced enhanced levels of reactive oxygen species (ROS) and
showed increased protein oxidative damage, increased mitochon-
drial number and mass as well as mitochondrial hyperpolarization
[25,26]. These results suggest that intramitochondrial oxidative
stress is an important element in the pathogenesis of SA, and is
sufficient to induce pathologic iron accumulation in mitochondria
of developing RBC [27]. Characterization of sideroblasts isolated
from the marrows of patients with acquired or hereditary SA also
showed increased ROS production, oxidative damage to protein
and mitochondrial hyperpolarization—indicating that these fea-
tures are shared between the murine SOD2 model and clinical
samples [28]. In order to better characterize this unique
sideroblastic-like phenotype and to identify putative targets of
oxidative stress that may be important regulators of red cell
development or iron homeostasis, we compared erythroid
development and gene expression patterns between normal and
Sod2
-/- erythroid progenitors.
Results
Sod2
-/- erythropoiesis shows a maturational left shift
We used a FACS-based method tracking expression of the
erythroid-specific antigen TER-119 and CD71 (transferrin
receptor) [29,30] to compare normal and Sod2
-/- erythroid
differentiation (figure 1A) in murine bone marrow. Taken as a
whole, the CD71
Lo-Hi TER-119
Hi population encompassing the
early basophilic erythroblast to reticulocyte stages (gates R4-R6,
figure 1A) was increased in Sod2
-/- marrows. In particular,
CD71
Hi TER-119
Hi Sod2
-/- basophilic erythroblasts (R4) were
increased relative to normal (1.9-fold), and Sod2
-/- CD71
- TER-
119
Hi reticulocytes and mature RBC (R7) were decreased relative
(5.9-fold) to normal (bar graph, figure 1B). Sod2
-/- marrow showed
a mild erythroid hyperplasia with a 1.6-fold increase in numbers of
total erythroblasts (Gate R4 in figure 1C: FSC
Med-Hi PI
- TER-
119
+ CD71
+ cells) compared to normal marrow, consistent with
prior results [1].
Microarray-based differential gene expression study of
Sod2
-/- erythroblasts
In order to better understand functional consequences of loss of
SOD2 during erythropoiesis, we identified gene transcriptional
changes in erythroid progenitor cells using cDNA microarray-
based gene expression analysis. Erythroblasts were isolated from
marrow of reconstituted mice using a sorting gate (figure 1C
region R4) that includes regions R4-, R5- and R6-gated events
(from figure 1A) encompassing all developing erythroid cells co-
expressing TER-119 and CD71 for the preparation of total RNA.
By genotype, sorted cells did not show a significant difference in
cell size or morphology upon microscopic examination. Total
RNA (n=4 per genotype) was labeled and hybridized on
Affymetrix murine arrays to determine relative gene expression
between normal and Sod2
-/- erythroblasts.
Analysis of gene expression data
The GeneSifter program was used to identify and categorize
differentially expressed transcripts. Among the 476 differentially
expressed transcripts (identified using a minimum fold change of
61.5 and corrected p value ,0.05) 149 were expressed at higher
levels in Sod2
-/- erythroblasts, while 327 were down-regulated. A
scatterplot of comparative gene expression, with selected differen-
tially expressed transcripts identified, is shown in figure 2. The
most highly differentially down- and up-regulated transcripts
(showing a fold-change $62) are listed in tables 1 (down) and 2
(up). The entire dataset of 476 transcripts can be found in
supplementary data table S1. Overall there are more than twice as
many down-regulated transcripts in the Sod2
-/- samples.
We used gene ontology/pathway analysis [31] to identify
patterns of gene expression change characteristic of specific
pathways or biological functions affected by SOD2-deficiency.
The largest gene sets identified as significantly altered (with a Z-
score .62) [32] in Sod2
-/- erythroblasts comprised metabolic
pathways with a direct role in mitochondrial metabolism or
biogenesis. Nearly every enzyme in the tricarboxylic acid (TCA)
cycle was down-regulated at the transcriptional level (figure 3a).
The exception was the enzyme phosphoenolpyruvate carboxyki-
nase 2 (Pck2), a regulator of substrate flow between the TCA cycle
and glycolysis/gluconeogenesis. Similarly, loss of SOD2 profound-
ly effects transcription of multiple nuclear-encoded components of
all 5 mitochondrial respiratory chain complexes (figure 3b).
Mitochondrial protein synthesis is also targeted, with 42 nuclear
encoded ribosomal protein genes coordinately down-regulated in
Sod2
-/- erythroblasts (figure S1 shows a heat map of mitochondrial
ribosomal gene expression; all down-regulated $1.2 fold with
corrected p#0.05). Additional pathways that differ between
Sod2
+/+ and Sod2
-/- erythroblasts include spliceosome, DNA
repair and replication, purine and pyrimidine metabolism and
gene sets associated with Huntington’s and Parkinson’s diseases
(supplementary tables S2 and S3 list all pathways that differ
between Sod2
+/+ and Sod2
-/- with a Z-score . 62).
Gene Expression Changes in SOD2-/- Erythroblasts
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identified as known causes of sideroblastic anemia were queried for
differential expression. No significant differences were observed for
most genes involved in heme biosynthesis including ALAS-2 and
alpha and beta globin chains–which as expected were among the
most highly expressed transcripts in erythroblasts (figure 2). A
single transcript (Riken cDNA A230051G13) encoding a putative
aminomethyltransferase involved in heme biosynthesis was
expressed at higher levels in Sod2
+/+ cells (see supplemental figure
S2). Two genes involved in iron metabolism, transferrin receptor
(Tfrc) and ATP binding cassette family member b7 (ABCb7) were
differentially expressed. Tfrc, the cellular gatekeeper for iron, was
expressed at higher levels in Sod2
-/- cells (figure 4) at both the
mRNA and protein levels. ABCb7, previously shown to be mutated
in X-linked sideroblastic anemia with ataxia (XLSA/A—OMIM
301310) is decreased in Sod2
-/- cells (1.6 fold decrease, p=0.02,
unpaired t test). No other genes associated with iron metabolism,
heme biosynthesis or hereditary sideroblastic anemia showed
significantly different expression between groups. (supplemental
figure S2 shows expression heat maps and the list of genes from
these analyses).
Microarray validation at the transcript and protein levels
Expression at the gene and protein level of CD71, transferrin
receptor, was of particular interest as SOD2 deficient cells, similar
to sideroblasts in patients with SA, show iron overload in the
Figure 1. Sod2
-/- erythroid development is characterized by a maturational left shift. A. Sod2
-/- marrow (right) shows an increased fraction
of immature basophilic erythroblasts (R4 gate: 1.9-fold increase) and decreased numbers of reticulocytes and mature RBC (R7 gate: 6-fold decrease),
respectively, relative to Sod2
+/+ (left). Density dot plots, gated on FSC
Med-Hi PI
- cells, allowed the quantitative assessment of the maturational stages of
differentiating erythroblasts. Region definitions (clockwise): CD71
Med TER-119
Lo cells or primitive progenitor cells and proerythroblasts (R2), CD71
Hi
TER-119
Lo cells or proerythroblasts and early basophilic erythroblasts (R3), CD71
Hi TER-119
Hi cells or early and late basophilic erythroblasts (R4),
CD71
Med TER-119
Hi chromatophilic and orthochromatophilic erythroblasts (R5), CD71
Lo TER-119
Hi cells or late chromatophilic erythroblasts and
reticulocytes (R6), and CD71
- TER-119
+ reticulocytes and mature RBC (R7) (from [29,30]). B. Bar graph comparing the distribution of Sod2
+/+ and
Sod2
-/- erythroid progenitor cells in the regions defined above in panel A. Significant differences between groups were observed for: R4, 1.9 fold
increase in Sod2
-/- (26.3361.70% of gated Sod2
-/- [N=20] vs. 14.1061.20% Sod2
+/+ [N=17] cells; P,0.0001; % gated cells 6 SEM); R7, 5.9 fold
decrease in Sod2
-/- (0.5760.14% of gated cells vs. 3.3960.63%, respectively; P,0.0001; % gated cells 6 SEM; N= same as above). C. Dot plots show
the FACS gating strategy used to isolate FSC
Med-Hi TER-119
+ CD71
+ erythroblast populations (R4) for gene expression analysis. Sod2
-/- marrow showed
erythroid hyperplasia with a 1.6 fold higher number of erythroid progenitors (R4). Dot plots were gated on PI
- TER-119
+ events and allowed the
discrimination of three developmental stages: FSC
Med-Hi TER-119
+ CD71
+ erythroblasts (R4), FSC
Lo TER-119
+ CD71
+ reticulocytes (R3) and FSC
Lo TER-
119
+ CD71
- mature RBC (non-gated on figure). A, B; ***, P,0.0001; Sod2
+/+, N=17; Sod2
-/-, N=20. FACS profiles shown are representative of multiple
assays.
doi:10.1371/journal.pone.0016894.g001
Figure 2. Overview of gene expression comparison of Sod2
-/- vs. Sod2
+/+ erythroblasts. Scatterplot highlights genes expressed .1.5 fold
higher (red) or lower (green) in Sod2
-/- compared to Sod2
+/+ cells. X and Y axes plot relative expression values derived from microarray intensities.
Spots corresponding to selected highly differentially expressed genes are identified. Among the most highly expressed genes are the hemoglobin
alpha and beta chains, that show no difference between Sod2
-/- and Sod2
+/+ samples. In Sod2
-/- erythroblasts, there are more than twice as many
transcripts with reduced vs. increased expression. A full listing of differential transcripts (with corrected p,0.05 and fold-change .61.5) is in table S1.
doi:10.1371/journal.pone.0016894.g002
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expression of Tfrc found in Sod2
-/- erythroblasts was verified both
by FACS analysis of CD71 surface expression on bone marrow
cell suspensions (figure 4a) and by qPCR (figure 4b). Increased
expression of CD71 was not due to differences in cell size, as
normal and SOD2 deficient erythroid cells showed similar forward
scatter profiles and expressed comparable amounts of the Ter119
surface antigen, yet showed a 1.6 fold increase in transferrin
receptor 1 (CD71) surface expression, when comparing geometric
means of fluorescence intensity values.
Array data were validated by performing TaqMan Gene
Expression Assays on total RNA samples from independently
prepared TER-119
+ CD71
+ erythroblasts. 13/14 transcripts tested
by qPCR showed significant differential expression between
Sod2
-/- and Sod2
+/+ samples (2 with p,0.05, 11 with
p,0.0001) and all transcripts showed the expected direction of
change when comparing Sod2
-/- and Sod2
+/+ cells (figure 4b). The
validation set included genes with high, intermediate and low
expression levels, as well as the most highly up and down regulated
transcripts. Among the validation set are genes with highly
differential expression, but no previously described role in red cell
development or physiology—such as synuclein a Snca–2 fold up,
intraflagellar transport protein 140 (Ift140—20 fold down), GTP
cyclohydrolase (Gch1—6 fold up) and tuberous sclerosis 2 (Tsc2—2
fold down).
Discussion
In this study we have evaluated gene expression changes in
erythroblasts that result from knockout of the antioxidant protein
SOD2 in hematopoietic tissues—a model previously shown to
have many features of congenital or acquired sideroblastic anemia.
Comparative FACS analysis using erythroid specific markers
(Ter119 and CD71—figure 1) demonstrates a maturational shift in
SOD2 deficient marrow, with more immature cells, particularly
basophilic erythroblasts, relative to wild-type marrows. This is
consistent with prior work showing erythroid hyperplasia in spleen
and marrow of recipients of Sod2
-/- cells [1].
Table 1. List of Expressed Erythroblast Transcripts/Genes with Decreased Expression in Sod2+/+ Compared to Sod2-/- Cells.
Fold Change
Direction in
Sod2
+/+
Adjusted
p-value Gene ID Gene Name Gene Identifier UG Cluster
6.24 Down 0.0134 Gch1 GTP cyclohydrolase 1 NM_008102 Mm.10651
3.48 Down 0.0241 2410003J06Rik RIKEN cDNA 2410003J06 AK010362 Mm.379207
3.18 Down 0.0347 Hspa1b Heat shock protein (hsp68) M12573 Mm.372314
2.88 Down 0.0399 Mthfd2 Methylenetetrahydrofolate
dehydrogenase
BG076333 Mm.443
2.85 Down 0.0134 - ESTs BB450769 -
2.73 Down 0.0090 E4f1 Transcription factor phi AP3 NM_007893 Mm.163132
2.68 Down 0.0048 - Similar to E4F transcription factor 1 BB027397 Mm.445985
2.66 Down 0.0129 - Transcribed locus BM201499 Mm.450309
2.59 Down 0.0136 - ESTs BM247240 -
2.36 Down 0.0217 - Transcribed locus BM211430 Mm.413311
2.35 Down 0.0170 - Transcribed locus BB631473 Mm.437948
2.33 Down 0.0422 Plek2 Pleckstrin 2 NM_013738 Mm.103380
2.31 Down 0.0170 Epb4.1 Erythrocyte protein band 4.1 BB462549 Mm.30038
2.27 Down 0.0129 - Transcribed locus BB201490 Mm.445692
2.16 Down 0.0218 - DNA segment, Chr 5, ERATO Doi 255,
expressed
C79489 -
2.16 Down 0.0391 - Transcribed locus BE631223 Mm.472907
2.15 Down 0.0240 - DNA segment, Chr 10, ERATO Doi 276,
expressed
BG066654 -
2.13 Down 0.0182 - Transcribed locus BF461324 Mm.449557
2.12 Down 0.0129 - ESTs BB205419 -
2.09 Down 0.0324 Usp32 Ubiquitin specific peptidase 32 BG071170 Mm.178524
2.05 Down 0.0331 Cbfa2t3 CBF, runt domain, alpha subunit 2,
translocated to, 3
NM_009824 Mm.194339
2.04 Down 0.0428 - Transcribed locus BB471309 Mm.406286
2.03 Down 0.0347 Malat1 Metastasis associated lung adeno-Ca
transcript 1
AK020483 Mm.298256
2.03 Down 0.0397 - Transcribed locus BM240223 Mm.438431
2.02 Down 0.0170 Clcn3 Chloride channel 3, transcript variant a, BB328803 Mm.259751
2.01 Down 0.0399 Per1 Period homolog 1 AF022992 Mm.7373
2 Down 0.0397 D930015E06Rik RIKEN cDNA D930015E06 BB547420 Mm.28838
(Fold Change $2 and corrected p,0.05.).
doi:10.1371/journal.pone.0016894.t001
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involved in mitochondrial metabolism, with multiple transcripts
encoding proteins involved in oxidative phosphorylation, ATP
synthesis, TCA cycle and mitochondrial biogenesis down-regulat-
ed in Sod2
-/- erythroblasts (figure 3). An analogous global decline
in activity was found when measuring mitochondrial respiratory
complex activity in tissues of Sod2
-/- neonates prior to death
[24,33]. In particular, nuclear-encoded components of all 5
mitochondrial respiratory complexes showed reduced transcript
levels, as did multiple enzymes in the TCA cycle. An exception
was the TCA cycle enzyme phosphoenolpyruvate carboxykinase 2
(Pck), that showed an increase in expression in SOD2 deficient
cells. Pck converts the TCA cycle anion oxaloacetate to
phosphoenolpyruvate, which can in turn be converted to pyruvate
by pyruvate kinase (PK) or to glucose. Increased expression of
Pck2 suggests that substrates are being shunted away from the
TCA cycle toward glycolysis/gluconeogenesis in Sod2
-/- cells [34].
A major mechanism underlying the development of mitochon-
dria-related diseases is thought to be an increase in intracellular
oxidative stress resulting from impairment of the mitochondrial
electron transport chain (ETC) [35,36]. Our microarray results
show that in the context of SOD2 deficiency, oxidant stress leads
to a broad down-regulation of genes encoding components of the
respiratory chain. This may be due to a direct effect of superoxide
on a signaling pathway between the nucleus and mitochondria, or
may result from a decline in the function of oxidant sensitive
components of the electron transport chain (such as Fe:S
containing proteins)—resulting in a metabolic imbalance that
triggers mitochondrial-to-nuclear communication.
Widespread down regulation of expression of nuclear encoded
mitochondrial genes/proteins suggests engagement of a feedback
loop controlling transcription of nuclear-encoded mitochondrial
proteins. Candidate components of such a feedback loop include
the related nuclear coactivators PGC1a, PGC1b and PPRC1,
which regulate expression of many proteins involved in oxidative
phosphorylation and mitochondrial biogenesis [37,38,39], includ-
ing many genes in the set of down regulated messages in Sod2
-/-
erythroblasts. A prior study investigating erythroid development
from hematopoietic stem cells deficient in the tumor suppressor
Rb implicated PGC1b as a regulator of erythroid development
[40]. PGC1a and PGC1b transcript levels were very low in
erythroblasts and did not differ between normal and Sod2
-/- cells
either in microarray or subsequent qPCR experiments (data not
shown). Expression of the related coactivator, PPRC1 [37] was
both higher, and differential when comparing Sod2
-/- and normal
erythroblasts on microarray (1.6 fold . in Sod2
+/+ vs. Sod2
-/-,
Table 2. List of Expressed Erythroblast Transcripts/Genes with Increased Expression in Sod2+/+ Compared to Sod2-/- Cells.
Fold
Change
Direction
in Sod2
+/+
Adjusted
p-value Gene ID Gene Name Gene Identifier UG Cluster
20.11 Up 0.0008 Ift140 Intraflagellar transport 140 homolog NM_134126 Mm.32802
4.46 Up 0.0493 Slc15a2 Solute carrier family 15 (H+/peptide transporter) member 2 NM_021301 Mm.281804
3.96 Up 0.0397 - Transcribed locus AW493533 Mm.441111
3.54 Up 0.0129 Unkl Unkempt-like AK004898 Mm.267353
3.23 Up 0.0297 Aldh1a7 Aldehyde dehydrogenase family 1, subfamily A7 NM_011921 Mm.14609
3.04 Up 0.0379 - murine leukemia retrovirus BG297038 -
2.71 Up 0.0420 - 2,3-cyclic nucleotide 3 phosphodiesterase BB251922 -
2.7 Up 0.0347 Cd79a CD79A antigen NM_007655 Mm.1355
2.55 Up 0.0440 Cdk4 Cyclin-dependent kinase 4 NM_009870 Mm.6839
2.54 Up 0.0391 Spib Ets transcription factor Spi-B BM244106 Mm.8012
2.4 Up 0.0411 Selenbp2 Selenium binding protein 2 NM_019414 Mm.225405
2.37 Up 0.0241 Scd1 Strain BALB/c stearoyl-coenzyme A desaturase 1 NM_009127 Mm.267377
2.33 Up 0.0493 Cd79b CD79B antigen NM_008339 Mm.2987
2.26 Up 0.0170 Tgtp T-cell specific GTPase NM_011579 Mm.15793
2.25 Up 0.0428 - Transcribed locus BB534670 Mm.406799
2.13 Up 0.0170 Cnp 2,3-cyclic nucleotide 3 phosphodiesterase M58045 Mm.15711
2.13 Up 0.0170 Hmgn1 High mobility group nucleosomal binding domain 1 NM_008251 Mm.2756
2.1 Up 0.0347 Msh6 MutS homolog 6 U42190 Mm.18210
2.08 Up 0.0396 Car1 Carbonic anhydrase 1 BC011223 Mm.273195
2.07 Up 0.0315 Ifit1 Interferon-induced protein with tetratricopeptide repeats 1 NM_008331 Mm.439751
2.07 Up 0.0428 2900010J23Rik RIKEN cDNA 2900010J23 BI144310 Mm.27344
2.06 Up 0.0493 Tmem179b Transmembrane protein 179B NM_026325 Mm.45155
2.06 Up 0.0170 Lgals9 Lectin, galactose binding, soluble 9 NM_010708 Mm.341434
2.05 Up 0.0347 C1qbp Complement component 1, q subcomponent binding protein NM_007573 Mm.30049
2.05 Up 0.0347 Fam132a Family with sequence similarity 132, member A NM_026125 Mm.29140
2.02 Up 0.0312 Hspb6 Heat shock protein, alpha-crystallin-related, B6 (Hspb6) BB755506 Mm.34885
2 Up 0.0241 Hn1l Hematological and neurological expressed 1-like AV116987 Mm.371601
(Fold Change $2 and corrected p,0.05.).
doi:10.1371/journal.pone.0016894.t002
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mitochondrial biogenesis during erythroid development. While
microarray analysis does not assess transcription of mitochondrial
DNA-encoded subunits of the respiratory chain, we also found
reduced expression (1.8-fold, with adjusted P,0.02) of the critical
nuclear encoded mitochondrial transcription factor A (Tfam)i n
Sod2
-/- erythroblasts. Tfam is required for the expression of
mitochondrial DNA-encoded genes, and is itself a target of
PGC1a [41] and, by analogy, a potential target of related family
members PGC1b and PPRC1. One prediction that follows from
decreased expression of Tfam would be a global decrease in
expression of mitochondrial encoded protein subunits of the ETC
in SOD2 deficient cells. Also consistent with the theme of
decreased mitochondrial biogenesis is the statistically significant,
but modest (1.2 to 1.6 fold) decrease in transcription of multiple
nuclear encoded mitochondrial ribosomal protein genes in Sod2
-/-
cells (supplementary figure S1).
Like human sideroblasts, SOD2 deficient erythroblasts do not
effectively utilize iron creating a paradoxical situation in which
cells are functionally iron-deficient despite (intramitochondrial)
iron overload. Microarray data revealed two differentially
expressed transcripts involved in iron homeostasis, Tfrc–encoding
transferrin receptor 1–that is expressed at higher levels in Sod2
-/-
cells (figure 4b), and ABCb7—a mitochondrial membrane localized
solute transport protein necessary for iron:sulfur cluster biogenesis.
Increased expression of Tfrc is likely to facilitate the observed
dramatic increase in iron content of SOD2 deficient cells by
enhancing iron delivery. In both figure 1A and figure 4A, we show
increased Tfrc protein expression by flow cytometric assay in
SOD2 deficient erythroid progenitors. This increased expression
reflects both the over-representation of basophilic erythroblasts
(which are CD71 high by definition) in the SOD2 deficient
marrow, and an incremental increase of Tfrc expression within
Sod2
-/- cells at this developmental stage. This incremental increase
in Tfrc expression may be mediated by changes in intracellular
iron regulatory protein function. Decreased expression of ABCb7
(down-regulated in SOD2 deficient cells 1.7-fold) may also exert
an effect on iron metabolism through a reduction in Fe:S cluster
assembly—and thereby impact iron homeostasis by altering the
level of iron regulatory protein 1 (IRP1). Under conditions of iron
deficiency, IRP1 activity increases as the apo protein (lacking an
Fe:S cluster) accumulates. IRP’s bind to regulatory sequences in
Figure 3. Sod2
-/- cells show decreased expression of multiple components of the TCA cycle and Electron Transport Chain. A.
Schematic of TCA cycle highlights those enzymes with reduced transcript levels. Degree of shading reflects the degree of transcript expression
change. The associated table shows enzyme name and fold change observed. Nearly every enzyme in the pathway shows a statistically significant
reduction in transcription, although the fold-change is modest. B. Schematic diagram of ETC complexes I-IV and ATP synthase highlights nuclear
encoded components with decreased expression in Sod2
-/- cells. The accompanying table lists specific subunit names along with the fold change
observed. Each complex shows decreased transcription of one or more nuclear encoded subunits. All highlighted subunits in panels A and B showed
statistically significant differential expression (p,0.05), with fold-change as indicated in table or by grey-scale.
doi:10.1371/journal.pone.0016894.g003
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RNA—promoting production of transferrin receptor protein
[42,43,44] thereby increasing iron delivery. Decreased transcrip-
tion of ABCb7 has been reported in CD34
+ cells isolated from
MDS patients with idiopathic acquired SA (RARS), suggesting
that ABCb7 is a critical, perhaps necessary target for the
derangement of iron metabolism that leads to generation of
ringed sideroblasts [45]. Interestingly, we find that Ciao1 [46,47], a
gene encoding a second protein required for a late step of
iron:sulfur cluster assembly, is also down-regulated in Sod2
-/- cells
(1.6-fold; p,0.0005 unpaired t test). The same argument can be
made that reduced Ciao1 activity has potential to alter erythroid
iron metabolism by tipping the balance toward generation of the
apo protein, IRP1.
At the level of gene expression profiling, the most prominent
effect of loss of SOD2 is a broad down-regulation of multiple
aspects of mitochondrial metabolism and biogenesis. This is
consistent with current knowledge regarding causes of hereditary
SA—where mutations affecting proteins that localize to mito-
chondria, or mitochondrial DNA itself have been shown to be
causal. SA is much more common later in life in the context of
myelodysplasia, where etiology remains uncertain. Our results
demonstrate that mitochondrial dysfunction (of diverse etiology)
can be a primary event in development in SA. In Sod2
-/-
erythroblasts oxidative stress affects erythroid-specific transcrip-
tional mechanism(s) that regulate expression of nuclear encoded
mitochondrial proteins. One consequence of such dysfunction is
altered iron metabolism secondary to impaired iron:sulfur cluster
synthesis resulting from down-regulation of ABCb7 and Ciao1—
which impacts both mitochondrial iron utilization and regulation
of iron metabolism. Identification of components of the mito-
chondrial biogenesis pathway active during erythroid differentia-
tion will be an important step toward improving our understand-
ing of the etiology of SA and will provide additional insights into
the relationship between mitochondrial dysfunction and develop-
ment of anemia. Novel insights into pathogenesis of sideroblastic
anemia may come from evaluation of the function of additional
candidate genes identified as strongly differentially expressed
between normal and Sod2
-/- erythroblasts, but with no previously
defined role in erythroid development. Evaluation of these loci in
both hereditary and acquired SA cases that lack mutations in
previously identified SA genes may identify novel mutations
associated with this disorder.
Materials and Methods
Ethics Statement
All animal experiments were conducted under an approved
protocol (ARC 06-0339) approved by the TSRI IACUC
committee. All work complies with relevant federal and state
regulations concerning use of animals.
Mice and reagents
Female B6 mice reconstituted with Sod2
+/+ or Sod2
-/- HSC
were generated as previously described [1]. Hematopoietic
chimeric animals were tested for anemia by assaying hematocrit
and reticulocyte counts. Marrow was taken from femurs, tibias,
pelvic girdles and humerus after Halothane (Halocarbon Labora-
tories, River Edge, NJ) vapor terminal inhalation. All experiments
were conducted under an approved protocol (ARC 06-339)
approved by the TSRI IACUC committee. All work complies with
relevant federal and state regulations concerning use of animals.
All monoclonal antibodies (mAbs) were purchased from Pharmin-
gen (BD Biosciences, San Jose, CA) save a FITC-rat IgG1, k
isotype control mAb (eBioscience, Inc., San Diego, CA). LS & LD
MACS columns and MidiMACS separator units were purchased
from Miltenyi Biotech (Auburn, CA, USA); and phenol red–free
RPMI 1640 media from Invitrogen (Carlsbad, CA, USA).
Propidium iodide (PI) and Hybri-Max RBC lysing buffer were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Erythroblast sorting for microarray
Bone marrow cell suspensions were labeled with a purified anti-
CD16/32 mAb for cell surface Fc fragment receptors (FcR)
saturation, FITC-conjugated anti-CD71 and PE-conjugated anti-
TER-119 mAbs in ice-cold fluorescence-activated cell sorting
(FACS) buffer (2 mM EDTA: 0.5% BSA: PBS). Cells were
resuspended in sorting buffer (1 mM EDTA: 25 mM HEPES: 1%
FCS: 10 mg/ml PI: PBS). Two pairs of Sod2
+/+ and Sod2
-/-
samples were sorted in parallel using two FACSDiva and two
FACSAria sorters (BD Biosciences). Ter119
+, CD71
+ erythroblasts
corresponding to gate R4 in Figure 1C were used for microarray
analysis.
Positive selection of TER-119
+ erythroid progenitors for
quantitative real-time RT-PCR (qPCR)
RBC-depleted bone marrow cell suspensions were labeled with
a biotinylated TER-119 mAb; TER-119
+ cells were pulled down
with streptavidin MicroBeads (Miltenyi Biotec) according to the
manufacturer’s instructions. Purity and cell morphology were
evaluated by FACS analysis and microscopic examination of
Wright-Giemsa-stained sorted cells cytospun onto slides, respec-
tively. Ter-119
+ cells represented 85.78%61.6% of magnetically-
purified cells from whole marrow suspensions with
81.94%63.23% viability (N=7; trypan blue exclusion; not
shown). We extracted and average of 8.29 (61.16) micrograms
total RNA from 18.82 (63.90)610
6 purified erythroid progenitors
Figure 4. Validation of Microarray Results at Protein Level (CD71) and by qPCR. A. Transferrin Receptor Expression: Smoothed histograms
excluding dead cells display (i) CD71, (ii) TER-119, (iii) FSC height vs. cell counts. Bone marrow cell suspensions were labeled with anti-TER-119, -CD71
or isotype control mAbs plus propidium iodide, and were assayed by FACS. Events were gated on FSC
Med-Hi PI
- TER-119
+ cells. Staining specificity was
determined by comparison with staining using an isotype control mAb for CD71 (not shown). Sod2
+/+ and Sod2
-/- cells express similar levels of TER-
119 antigen (13196145.30 vs. 13526140.60) and have similar forward scatter profiles (103.8061.35 vs. 106.5061.64), yet Sod2
-/- cells show a 1.6-fold
increase in transferrin receptor 1 (CD71) expression (528.80651.07 vs. 851.10657.29, Sod2
+/+ vs. Sod2
-/-). This increase appears to represent both a
developmental shift (see figure 1A), and an increase in absolute expression within individual cells. Values presented are geometric mean fluorescence
intensity (Geo MFI) 6 SEM; Sod2
-/-, N=20; Sod2
+/+, N=17; ***, P,0.0001. B. qPCR validation of microarray study: Graph shows the relative expression
of 14 transcripts determined by qPCR. Expression levels in Sod2
-/- erythroblasts (grey) are presented relative to Sod2
+/+ samples as calibrator (black);
the latter being given an expression level of 1 (Log10(1)=0), Log10 transformed and vertically stacked. TaqMan assays were chosen so that they
covered a wide range of expression from the most down-regulated to the most up-regulated transcripts in Sod2
-/- erythroblasts. Results were
normalized to the expression of eukaryotic 18S rRNA as endogenous control. 13/14 transcripts were significantly different between Sod2
+/+ and
Sod2
-/- samples. All transcripts showed the expected direction of differential expression based upon microarray results. RQ, relative quantity (X axis);
mean 6 SEM; N=4 biological replicates per genotype, run in technical triplicates; figure indicates p values from unpaired, 2 tailed t test.
doi:10.1371/journal.pone.0016894.g004
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reactions.
FACS analysis
Cell suspensions were labeled with purified anti-CD16/32 (FcR
saturation), FITC-conjugated anti-CD71 and PE-conjugated anti-
TER-119 mAbs in ice-cold FACS buffer. 10 mg/ml PI was added
prior to analysis on a FACSCalibur cytometer running CellQuest
Pro (BD Biosciences). Gating distinct stages of erythroid
development (figure 1A) was based upon scheme of Socolovsky
[29]. Anti-CD71 labeling specificity was validated by the use of a
FITC-rat IgG1, k isotype control mAb (eBioscience, San Diego,
CA).
Total RNA extraction from erythroid cells
Total RNA was extracted using the RNeasy Mini kit (Qiagen,
Inc., Valencia, CA) accordingly to the manufacturer’s suggested
protocol for isolation of Total RNA from animal cells. Briefly, we
disrupted and lysed 12.6561.90 million sorted cells (N=8) in
RLT Buffer, homogenized and sheared genomic DNA through
centrifugation on QIAshredder spin columns; we performed on-
column DNA digestion with the RNase-Free DNase Set (Qiagen)
and eluted total RNA in RNase-free water (Sigma-Aldrich).
Oligonucleotide arrays
All experiments were performed using GeneChip Mouse
Genome 430 2.0 and GLYCOv2 oligonucleotide arrays (Affyme-
trix, Santa Clara, CA), as described at http://www.affymetrix.
com/products/arrays/specific/mouse430_2.affx and http://www.
functionalglycomics.org/static/consortium/resources/resourcecoree.
shtml, respectively. GLYCOv2 oligonucleotide arrays are custom
GeneChip arrays designed for the Consortium for Functional
Glycomics (CFG, http://www.functionalglycomics.org/).
RNA target preparation and array processing
Labeling. Total RNA from each sample was used to prepare
biotinylated target RNA using standard Affymetrix protocol
(http://www.affymetrix.com/support/technical/manual/expression_
manual.affx) as previously described [48]. Briefly, 5 mgo ft o t a l
RNA was used to generate first-strand cDNA by using a T7-linked
oligo(dT) primer. After second-strand synthesis, in vitro trans-
cription was performed with biotinylated UTP and CTP (Enzo
Life Sciences, Farmingdale, NY). Hybridization: the target
cRNA generated from each sample was processed as per
manufacturer’s recommendation using a GeneChip Instrument
System (Affymetrix). Briefly, spike controls were added to 6.7 mg
and 10 mg fragmented cRNA before overnight hybridization on
GLYCOv2 and 430 2.0 arrays, respectively. Post-processing
and scanning: arrays were then washed and stained with
streptavidin-phycoerythrin, before being scanned on a ScanArray
3000 (Affymetrix) using default settings and a target intensity of
250 for scaling. Quality control (QC): The amount and quality
of starting total RNA and cRNA were checked with a ND-1000
Spectrophotometer (NanoDrop Technologies, Inc., Wilmington,
DE) and an Agilent Bioanalyzer (Agilent Technologies, Palo Alto,
CA), respectively, and/or on formaldehyde-containing agarose
gels. After scanning, array images were assessed by eye to confirm
scanner alignment and the absence of significant bubbles or
scratches on the chip surface. GAPDH and b-actin 39/59 ratios
were confirmed to be within acceptable limits although one
Sod2
-/- specimen, showed slight RNA degradation. Gene Sifter
analyses performed with and without this 4
th Sod2
-/- sample
yielded similar results, and all figures/tables are derived from a
464 chip comparison. BioB spike controls were found to be
present on all chips, with BioC, BioD and CreX also present in
increasing intensity. When scaled to a target intensity of 250 using
the GeneChip Operating Software (GCOS) v1.3.037 algorithm
(Affymetrix), scaling factors for all arrays were within acceptable
limits (8.218-12.594 for GLYCOv2 chips, 4.089-7.955 for 430 2.0
arrays), as were background (42-68 for GLYCOv2, 48-67 for 430
2.0), Q values and mean intensities. Details of QC measures can be
found at https://www.functionalglycomics.org/glycomics/
publicdata/microarray.jsp, by clicking on the ‘Raw Data’i c o n
link for microarray experiment ‘Jeff Friedman 1: Sod2 KO anemic
mice’.
Microarray data analysis. Data presented were generated
using GeneSifter (VizX Labs, Seattle, WA) based pairwise analysis,
RMA-normalized. CEL files (N=4 Sod2
+/+; N=4 Sod2
-/-) and
were filtered upon the following criteria: a 61.5 or 1.2 ratio cutoff
(fold change, F.C.), t-test with Benjamini and Hochberg MTC to
adjust for false positives, FDR [49,50] and adjusted P value ,0.05.
Using these parameters, we found 476 discriminant transcripts at a
61.5 fold change (supplement table S1), and 2565 at a 61.2 fold
change. MIAME-compliant data discussed in this publication has
been deposited at the CFG (https://www.functionalglycomics.
org/glycomics/publicdata/microarray.jsp; GLYCOv2 arrays), in
NCBIs Gene Expression Omnibus (GEO, http://www.ncbi.nlm.
nih.gov/geo/) and is accessible through GEO Series accession
number GSE8726 (Mouse Genome 430 2.0 arrays). Gene
ontology and KEGG pathway analyses were performed in
GeneSifter to identify affected pathways. The entire gene
expression dataset (unfiltered for threshold or statistical
significance) was used to query expression of sets of genes of
interest (for example: heme biosynthesis, sideroblastic anemia, iron
metabolism as presented in supplementary data).
Two-step TaqMan Gene Expression Assays. Total RNA
was concentrated with a DNA100 SpeedVac Concentrator
(Savant) and reverse transcribed using the High-Capacity cDNA
reverse transcription (RT) kit (Applied Biosystems Inc., Foster
City, CA). We performed quantitative real-time PCR (qPCR)
using 30 ng cDNA template and the TaqMan Gene Expression
Master Mix (ABI) in singleplex reactions on a 7900HT Fast Real-
Time PCR System running SDS 2.3 (ABI) in default thermal
cycling conditions and endpoint data collection. QC and
amplification specificity of all targets was confirmed by melting
curve analysis. Data analysis was performed using the RQ
Manager 1.2 software (ABI) in DDCt relative quantification
mode. Eukaryotic 18S rRNA was used as endogenous control;
results were expressed relative to Sod2
+/+ samples as calibrator
and being given an expression level of 1 [51]. Average Ct values
for both Sod2
-/- and control Sod2
+/+ samples were based on 4
biological replicates; the Ct value for each biological replicate was
the average of technical triplicates. Part numbers of the used assays
are shown in supplementary data table S4.
Statistical analysis
Unpaired two-tailed t-tests were performed using GraphPad
Prism (GraphPad Software, San Diego, CA); results are shown as
mean 6 SEM; replicate numbers (N).
Supporting Information
Figure S1 Heat Map of Mitochondrial Ribosomal
Protein Gene Expression. 42 Distinct nuclear encoded
mitochondrial ribosomal protein genes are expressed differentially
when comparing Sod2
+/+ and Sod2
-/- samples. Data were filtered
to display transcripts with $1.2 fold change and a corrected p
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transcripts are down regulated in Sod2
-/- erythroblasts. 3 of the
listed genes appear twice and are represented by 2 distinct probe
sets.
(DOC)
Figure S2 Heat Maps Showing Genes Involved in: Iron
Ion Homeostatis, Heme Biosynthesis, or Etiology of
Sideroblastic Anemia. Expression of genes annotated as
playing a role in iron homeostasis and heme biosynthesis is
displayed for both Sod2
+/+ and Sod2
-/- samples without statistical
filtering for fold change or significance. When statistical filters
were applied to the set of iron homeostasis genes, ABCb7 and Tfrc
were the only genes expressed with a fold change $1.5 and p value
,0.05. ABCb7 is down in Sod2
-/- cells, while Tfrc expression is up.
Similarly, genes involved in heme biosynthesis are displayed
without filtering on the right. When statistical filters were applied,
a putative cDNA (Riken A230051G13) with a proposed role in
glycine catabolism and heme biosynthesis was found to be
expressed at higher levels in Sod2
+/+ cells, meeting the same
fold-change and statistical criteria. Finally, genes previously
identified as mutated in hereditary sideroblastic anemia were
queried for expression. Of these genes, only ABCb7 was (again)
found to be significantly differentially expressed. Sod2 appears in
the list of iron homeostasis related genes without showing
differential expression. This reflects detection of expressed (but
deleted for exon 3, and therefore nonfunctional [24]) mRNA in
the Sod2-/- cells, as some of the probesets on the microarray for
detecting this gene are outside of the deleted exons.
(DOC)
Table S1 List of 476 Differentially Expressed Tran-
scripts Comparing Sod2
-/- and Sod2
+/+ Erythroblast
Samples. Criteria used in filtering data were fold change 61.5
with a corrected p value ,0.05 (Benjamini and Hochberg MTC
used).
(DOC)
Table S2 KEGG Pathway Analysis of the 476 most
highly differentially expressed genes. The GeneSifter
program was used to generate a list of KEGG pathways using
the 476 differentially expressed transcripts (fold change 61.5 and
corrected p ,0.05) from table S2 that differ between groups. The
top section of table shows results for all 476 differentially expressed
transcripts, the middle panel shows analysis of only those
transcripts that were expressed at higher levels in Sod2
-/- cells,
while the bottom panel shows only those transcripts that were
expressed at lower levels in Sod2
-/- cells. In evaluating the
significance of identified pathways, a Z score greater than 2 is
considered significant. However, the low number of identified
genes in the set of transcripts with increased expression in Sod2
-/-
cells reduces confidence in some assignments. The strongest
assignments are to metabolic pathways, splicing, and DNA repair.
Several (strong) assignments are based upon overlapping gene sets
(predominantly components of the oxidative phosphorylation
pathway)—for instance Parkinson’s and Huntington’s Diseases,
where a mitochondrial link to pathogenesis has been identified.
(DOC)
Table S3 KEGG Pathway Analysis of Entire Microarray
Dataset. As in table S3 above, GeneSifter was used to identify
affected KEGG pathways utilizing the entire microarray dataset
(.45,000 ‘genes’ on the Affymetrix mouse genome 430 2.0 array).
This provides a much broader view of altered metabolic, signal
transduction and disease processes that share patterns of gene
expression change with those seen in our comparison of Sod2
+/+
versus Sod2
-/- erythroblasts.
(DOC)
Table S4 Taqman Assays Used for qPCR Validation:
Table S4 lists the endogenous control (18S), analyzed genes and
the corresponding inventoried transcript-specific assays (Applied
Biosystems Inc, Foster City, CA). Assays were selected with the
_m1 suffix; they are designed on exon/intron junctions and do not
amplify genomic DNA.
(DOC)
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